🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05743140
Recruiting Observational

A Clinical Study of Fundus OCTA for the Identification of CMD

NCT05743140 · tracked via the Priya Life Science China tracker
Sponsor
Peking University First Hospital
Phase
Observational
Started
2023-03-01
Last updated
2025-08-12

Condition(s) studied

Coronary Microvascular Disease

Investigational drug(s) / intervention(s)

CaIMR

CaIMR: Investigators diagnose CMD with CaIMR. Investigators use OCT and OCTA to analyze the fundus microcirculation quantitatively.

Study summary

Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital; 2. Complete baseline clinical information; 3. Subject who have coronary angiography results, which shows coronary stenosis \< 50%; 4. Older than 18 years; 5. Subjects who have signed informed consent. Exclusion Criteria: 1. Present serious fundus disease 2. Severe cataract and other ophthalmic diseases, which affect imaging quality; 3. Target coronary vessels provide collateral circulation for chronic complete occlusive lesions; 4. The target coronary angiography agent is poorly filled, overlapped, or severely distorted, and cannot fully expose the location of the lesion; 5. Coronary angiography images are of poor quality and cannot be identified; 6. Active bleeding state; 7. Severe renal insufficiency, contrast agent allergy, and unable to perform coronary angiography.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking university first hospital Beijing Beijing Municipality Recruiting

More Peking University First Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05743140 on ClinicalTrials.gov ↗ ← All trials in China